Reportstack has announced a new market research publication on Rheumatology Therapeutics Market to 2018 - Increasing Uptake of Benlysta, Uloric, Krystexxa, and the Launch of Oral Tofacitinib to Spur Growth which provides insights into the rheumatology therapeutics market forecasts until 2018 and examines global treatment usage patterns for various rheumatology disorders. It also looks at the geographical distribution of the rheumatology disorders therapeutics market across key geographies (the US, the top five countries of Europe, and Japan) and provides insights into the R&D pipeline and promising future blockbusters until 2018. The report also profiles major biopharmaceutical companies in the segment and analyzes M&A activity and licensing agreements.
The reports covers Rheumatoid Arthritis (RA), Osteoarthritis (OA), Systemic Lupus Erythematosus (SLE) and gout, as these are most prevalent forms of rheumatologic disease. The global rheumatology therapeutics market was estimated to be worth $17.1 billion in 2011, having grown at a Compound Annual Growth Rate (CAGR) of 9.4% from 2005, and is forecast to grow at a CAGR of 4.8% to $23.8 billion by 2018.
Enbrel (etanercept), Humira (adalimumab) and Remicade (infliximab) are the major drugs used in rheumatology therapeutics. Enbrel and Humira account for the majority of the market in the US. Enbrel's patent is set to expire in October 2012, although this is not expected to have an immediate impact as biosimilars are not predicted to enter the market until 2016-2017. In March 2011, the Food and Drug Administration (FDA) approved Benlysta (belimumab) for the treatment of SLE and in July 2011, it was approved by the European Medicines Agency (EMA).
Scope
Data and analysis for the rheumatology therapeutics market in the leading geographies of the world: the US, the UK, Germany, France, Italy, Spain and Japan
Annualized market data for the rheumatology therapeutics market from 2005 to 2011, forecast to 2018
In-depth analysis of the acute and chronic rheumatology therapeutics markets
Market data for the geographical and therapeutic landscapes, including size, annual cost of therapy, revenues, and treatment usage patterns for the diseased population, treatment-seeking population, diagnosed population and prescription population
Key drivers and barriers that have had a significant impact on the market
Profiles of major biopharmaceutical markets in the rheumatology therapeutics segment, namely AstraZeneca, Eli Lilly, Pfizer, Janssen Biotech and UCB
Key M&A activity and licensing agreements from 2007 to April 2012 in the rheumatology therapeutics market
Reasons to buy
Build effective strategies for launching pipeline products by identifying potential geographies
Exploit in-licensing and out-licensing opportunities by identifying products to fill portfolio gaps
Develop key strategic initiatives by studying top competitors' key strategies
Develop market-entry and market-expansion strategies by identifying the geographic markets poised for strong growth
The reports covers Rheumatoid Arthritis (RA), Osteoarthritis (OA), Systemic Lupus Erythematosus (SLE) and gout, as these are most prevalent forms of rheumatologic disease. The global rheumatology therapeutics market was estimated to be worth $17.1 billion in 2011, having grown at a Compound Annual Growth Rate (CAGR) of 9.4% from 2005, and is forecast to grow at a CAGR of 4.8% to $23.8 billion by 2018.
Enbrel (etanercept), Humira (adalimumab) and Remicade (infliximab) are the major drugs used in rheumatology therapeutics. Enbrel and Humira account for the majority of the market in the US. Enbrel's patent is set to expire in October 2012, although this is not expected to have an immediate impact as biosimilars are not predicted to enter the market until 2016-2017. In March 2011, the Food and Drug Administration (FDA) approved Benlysta (belimumab) for the treatment of SLE and in July 2011, it was approved by the European Medicines Agency (EMA).
Scope
Data and analysis for the rheumatology therapeutics market in the leading geographies of the world: the US, the UK, Germany, France, Italy, Spain and Japan
Annualized market data for the rheumatology therapeutics market from 2005 to 2011, forecast to 2018
In-depth analysis of the acute and chronic rheumatology therapeutics markets
Market data for the geographical and therapeutic landscapes, including size, annual cost of therapy, revenues, and treatment usage patterns for the diseased population, treatment-seeking population, diagnosed population and prescription population
Key drivers and barriers that have had a significant impact on the market
Profiles of major biopharmaceutical markets in the rheumatology therapeutics segment, namely AstraZeneca, Eli Lilly, Pfizer, Janssen Biotech and UCB
Key M&A activity and licensing agreements from 2007 to April 2012 in the rheumatology therapeutics market
Reasons to buy
Build effective strategies for launching pipeline products by identifying potential geographies
Exploit in-licensing and out-licensing opportunities by identifying products to fill portfolio gaps
Develop key strategic initiatives by studying top competitors' key strategies
Develop market-entry and market-expansion strategies by identifying the geographic markets poised for strong growth
To view the table of contents and know more details please visit Rheumatology Therapeutics Market to 2018 report.
No comments:
Post a Comment